HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Hernando Insúa, A. Articles by Chasseing, N. A. Search for Related Content PubMed PubMed Citation Articles by Hernando Insúa, A. Articles by Chasseing, N. A.

TECHNOLOGY DEVELOPMENT

IMT504, the Prototype of the Immunostimulatory Oligonucleotides of the PyNTTTTGT Class, Increases the Number of Progenitors of Mesenchymal Stem Cells Both In Vitro and In Vivo: Potential Use in Tissue Repair Therapy

^aImmunotech S.A., Buenos Aires, Argentina;
^bInstituto de Investigaciones Biomédicas, Fundación Pablo Cassará, Buenos Aires, Argentina;
^cInstituto de Biología y Medicina Experimental, Consejo Nacional de Investigaciones Científicas y Técnicas, Buenos Aires, Argentina

Key Words. Mesenchymal stem cell • Oligodeoxynucleotide IMT504 • Bone repair

Correspondence: Jorge Zorzopulos, Ph.D., Pavón 2885, Buenos Aires (C1248AAK), Argentina. Telephone: 54-11-43080501; Fax: 54-11-43080501; e-mail: zorzopul{at}hotmail.com

Received July 28, 2006; accepted for publication December 22, 2006.


Bone marrow (BM)-derived adult mesenchymal stem cells (MSCs) have the capacity to differentiate in vitro into different cell lines. This makes them a likely source for application in tissue repair therapies. Here, we report evidence indicating that, both in vivo and in vitro, IMT504, the prototype of the PyNTTTTGT class of immunostimulatory oligonucleotides, significantly increases the number of fibroblast colony-forming units (CFU-Fs) that originate MSCs. When rat BM cells were cultured with IMT504, the mean number of CFU-Fs increased about three times as compared with untreated controls (CFU-F: 19 ± 6.3 vs. 6.8 ± 2.0/2 x 10⁶ seeded BM cells, p = .03). Furthermore, rats inoculated with IMT504 had a significantly higher number of CFU-Fs both in BM (CFU-F: 124 ± 33 vs. 38 ± 17/femur, p = .04) and in peripheral blood (animals with detectable CFU-Fs in circulation 8/12 vs. 2/12, p = .04) as compared with untreated animals. On the other hand, BM-derived adherent cells either treated in vitro with IMT504 or obtained from animals injected with IMT504 possess the capacity to differentiate to the osteogenic and adipogenic cell lineages as regular MSCs. Finally, we found that repair of a bone defect was accelerated in rats injected with IMT504 as compared with control animals (area with consolidated bone: 80% ± 6.4% vs. 49% ± 3.5%, p = .03, n = 10 rats per group). Importantly, when two human BM were cultured in the presence of IMT504, the mean number of fibroblastic adherent colonies also increased as compared with controls. These results suggest the possibility of clinical use of IMT504 in bone, and presumably other, tissue repair therapies.

Disclosure of potential conflicts of interest is found at the end of this article.